74 results about "TLR7" patented technology

The invention belongs to the technical field of molecular biology, and particularly discloses a specific nano antibody targeting bovine TLR7 protein as well as a screening method and application of the specific nano antibody. The nano antibody can be specifically combined with a B cell antigen epitope of bovine TLR7 protein, and the B cell antigen epitope is selected from SEQ ID NO: 1 and / or SEQ ID NO: 2. The invention discloses a specific nano antibody targeting bovine TLR7 protein as well as a screening method and application of the specific nano antibody. The specific nano antibody targeting bovine TLR7 protein is high in stability and specificity and has super-strong affinity.

The invention discloses an SNP molecular marker combination related to disease resistance of ricefield eels and application of the SNP molecular marker combination, and relates to the technical field of molecular biology. The SNP molecular marker combination comprises the following molecular markers (1)-(3): (1) a molecular marker with a nucleotide sequence as shown in SEQ ID NO.7; (2) a molecular marker with a nucleotide sequence as shown in SEQ ID NO.8; and (3) a molecular marker with a nucleotide sequence as shown in SEQ ID NO.9. According to the invention, an SNP locus in a TLR7 gene in a monopterus albus group is screened through sequence alignment, and genotyping is carried out on the SNP locus; and comparing the differences of the disease resistance of the genotypes, and screening to obtain the genotype with the strongest disease resistance, thereby providing an effective molecular marker for detecting the disease resistance of the ricefield eel. The molecular marker combination provided by the invention is associated with the disease resistance of the monopterus albus, and provides effective technical support for breeding of disease-resistant monopterus albus varieties.

Provided in the present invention are an anti-TLR7 antibody or an antigen-binding fragment thereof, and a pharmaceutical composition thereof. The antibody or the antigen-binding fragment thereof can specifically bind to a human or simian TLR7 antigen and does not bind to murine TLR7, exhibits significant TLR7 antigen-binding activity, and can effectively inhibit various inflammatory cytokines produced upon TLR7 activation. The anti-TLR7 antibody or the antigen-binding fragment thereof can be used, either as a monotherapy or in combination with other drugs, for treating and / or preventing diseases pathologically associated with the TLR7 target, including immune inflammation-related diseases, allergic diseases, infectious diseases, cancers, etc.

The invention provides an anti-TLR7 antibody or an antigen binding fragment and a pharmaceutical composition thereof, the antibody or the antigen binding fragment thereof can be specifically bound with a human or monkey TLR7 antigen and is not bound with mouse TLR7, has remarkable TLR7 antigen binding activity, and can effectively inhibit various inflammatory cytokines generated by TLR7 activation. The anti-TLR7 antibody or the antigen binding fragment thereof can be used as a single agent or a drug combination and can be used for treating and / or preventing diseases related to TLR7 target pathology, including immune inflammation related diseases, allergic diseases, infectious diseases or cancers and the like.

The present application relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, as a Toll-like Receptor 7 (TLR7) agonist, for use in the treatment of lung cancer, a pharmaceutical combination of a TLR7 agonist and a tyrosine kinase inhibitor for use in the treatment of lung cancer, and the use of a compound of Formula I or a pharmaceutically acceptable salt thereof in the pharmaceutical combination in the treatment of lung cancer.

The invention provides a TOLL-like receptor 7 (TLR7) specific antagonist as well as a preparation method and application of the TOLL-like receptor 7 (TLR7) specific antagonist. The TLR7 antagonist has a structure as shown in a formula (I) or a formula (II), has outstanding TLR7 antagonistic activity and selectivity, and is expected to be applied to prevention and treatment of related diseases.

The present disclosure provides methods of treating or inhibiting cancer, reducing its severity, reducing its risk, or inhibiting its metastasis in an individual with a radiation-activated N-oxide TLR7 / 8 agonist.

Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.

Lipidized oxoadenines of formula (I) are TLR7 / 8 receptor ligands useful for modulating immune responses. These compounds may have therapeutic applications in the treatment of cancer, infectious diseases, allergies, or autoimmune disorders (SEE FORMULA).

Lipidated oxoadenines of formula (I) are TLR7 / 8 receptor ligands useful for modulating immune responses. The compounds may have therapeutic application in the treatment of cancer, infectious diseases, allergy, or autoimmune disorders.

Stable aqueous formulations of adjuvant comprising a TLR7 / 8 agonist or a TLR4 agonist with a helper lipid that are adsorbed to alum are provided. Compositions and methods of using the formulations for stimulating an immune response are also provided.

The present invention relates to a conjugate of cholesterol and a TLR7 agonist that is useful as a drug, a pharmaceutically acceptable salt thereof, and a drug composition or cancer treatment vaccine containing the same as an active ingredient.

The invention relates to the technical field of medicine, in particular to a nitrile compound and application of the nitrile compound in disease treatment medicine, and the chemical structural formula of the nitrile compound is shown in the formula I in the specification. The invention also provides a pharmaceutical composition containing the compound. The invention finds that the compound with the nitrile structure shows an excellent TLR7 agonist effect and can be used for treating diseases related to TLR7.

The present invention provides a method for activating an N-oxide TLR7 / 8 agonist using radiation and a method for treating or inhibiting cancer, reducing its severity, lowering its risk, or inhibiting metastasis.

This invention discloses a photoactivated nanoparticle-based drug delivery material for immunoadjuvants, its preparation method, and its applications. The drug delivery material is constructed from photosensitizer monomers, crosslinking monomers, and immunoadjuvant prodrug monomers within a confined space of a nanoemulsion via a copper-free click polymerization reaction to form crosslinked polymer nanoparticles. The nanoparticle size is controllable, and the composition is precisely defined. Under physiological conditions, the drug delivery material exhibits good colloidal stability and high drug loading. Upon near-infrared light irradiation, the generated ROS can cleave the thioketone bonds, causing the nanoparticles to depolymerize and achieving photo-triggered, controllable release of the immunoadjuvant. Under photodynamic action, this drug delivery material efficiently generates reactive oxygen species to induce immunogenic cell death in tumor cells. Simultaneously, the released immunoadjuvant activates the TLR7 / 8 pathway, promotes dendritic cell maturation, and enhances the systemic anti-tumor immune response, thereby inhibiting the growth of tumors in situ and at distant sites, and reducing the risk of metastasis and recurrence.

An imidazo [2,1-f] [1,2,4] triazin-4-amine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof which are used as a TLR7 agonist in the treatment of cancer are provided. Pharmaceutical compositions comprising the imidazo [2,1-f] [1,2,4] triazin-4-amine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof are also provided.

The present invention relates to compounds of formula (I) and pharmaceutically acceptable compositions thereof useful as toll-like receptor 7 / 8 (TLR7 / 8) antagonists.SOLUTION: In Formula (I), ring A is aryl or heteroaryl; ring B is aryl or heteroaryl; and X is C (R4) 2, O, NR4, S, S (R4), or S (R4) 2.SELECTED DRAWING: None

The invention discloses an application of 8-methyl quercetin in preparation of a TLR7 (toll-like receptor 7) immunomodulator. According to the invention, it is found that 8-methyl quercetin can be used as a ligand of TLR7, and the 8-methyl quercetin has strong binding and interaction with swine TLR7 protein. Therefore, the 8-methyl quercetin can be used as an immunomodulator or a lead compound acting on the TLR7. As the TLR7 protein is conservative in evolution, the application of the 8-methyl quercetin is not limited to pigs, and the 8-methyl quercetin can also be applied to other species.

The invention relates to a compound as shown in a formula (I) and an isotope form, a stereoisomer, a tautomer, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, hydrate, prodrug and polymorphic substance thereof, the compound as shown in the formula (I) can be used as a TLR inhibitor, effectively inhibits the expression level of TLR, especially double inhibition on TLR7 / 8, and can be used for preparing a TLR inhibitor. The compound has a good application prospect in the aspect of preparing medicines for treating TLR activity mediated diseases.

The present disclosure describes methods, compositions, and kits related to the combination of a TLR7 modulating compound and an HIV vaccine. The combination can be used in a method of treating or preventing an HIV infection in a human.

A compound of Chemical Formula 1 or a pharmaceutically acceptable salt thereof is disclosed. The compound inhibits a toll-like receptor (TLR) signaling pathway. A composition containing the compound and uses thereof are disclosed. The novel compound blocks the TNF-α secretion by inhibiting the expression and activation of NF-κB- and MAPK-related proinflammatory genes, and thus can be utilized as a therapeutic agent for many autoimmune diseases, such as systemic lupus erythematosus, psoriasis and psoriatic arthritis, associated with a hyperactivity of a nucleic acid:

The present invention relates to the use of a STING agonist, of a TLR5 agonist or of a TLR7 agonist for enhancing the number of p16high immune cells in vitro or in a patient in need thereof, in particular to extend health span and protect tissues against aging. It is also herein reported that p16high immune cells surprisingly play a key role in establishing disease tolerance, and can be useful for counteracting different lethal conditions, including LPS-induced sepsis, acute lethal SARS-CoV-2 infection, cancer and ionizing irradiation. The present invention thus relates to a pharmaceutical composition comprising autologous or heterologous p16high immune cells such as p16high CAR-T cells, and its use for various therapeutic purposes. These cells are preferably obtained by contacting them with a STING agonist, a TLR5 agonist and / or a TLR7 agonist.

The invention provides a cyclopropane TLR7 and / or 8 inhibitor (or antagonist) which can be used for preventing and / or treating inflammatory and autoimmune diseases and the like.

The application discloses an injection containing a compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, and a preparation method of the injection. The preparation method of the injection is simple, the quality of the injection is stable, the injection is convenient for clinical administration, and the injection meets the requirements of subsequent clinical tests.

The application discloses a photosensitive carrier and a preparation method and application thereof, and belongs to the field of nanomaterials.The application relates to a glutathione-activated nano-immunopreparation compound with targeting property, and a structural general formula of the compound is shown as formula I.The photosensitive carrier is prepared by wrapping a TLR7 agonist in the nano-immunopreparation compound, so that the photosensitizer and the immunodrug activity are inhibited, the tumor-related antigens released after the photodynamic killing are combined with the activated immune checkpoint inhibitors to jointly induce a synergistic antitumor immune response, so that the growth of in-situ / distant tumors is inhibited and tumor metastasis is prevented; the activated photodynamic immunopreparation molecules not only realize synergistic treatment and obtain excellent tumor treatment efficiency, but also can avoid serious side effects in the tumor treatment process.

The present invention provides a bovine sex-sorted sperm sorting solution mediated by a small molecule compound and its application. The sperm sorting solution comprises a sperm sorting protection solution and a sex control functional component. The sperm sorting protection solution contains sodium chloride, potassium chloride, calcium chloride dihydrate, sodium dihydrogen phosphate, glucose, sodium pyruvate, sodium bicarbonate, penicillin-streptomycin, and phenol red. The sex control functional component includes creatine and a 24e drug. The concentration of creatine is 450 μM-550 μM, and the concentration of the 24e drug is 0.27 μM-0.33 μM. The 24e drug is a pyrido [3,2-d]pyrimidine-based TLR7&8 dual agonist. The present invention can meet the large demand for sex-sorted semen in production. Moreover, the sorting process is carried out under the suitable conditions for sperm and does not require complex treatment of sperm. It takes less time for sorting and causes less damage to sperm.

Compounds according to Formula (I) are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used alone or as part of an antibody-drug conjugate in cancer treatment, for example in combination with an anti-cancer immunotherapy agent. Such compounds may also be used as vaccine adjuvants.